Letters to the Editor

Inaccurate Information on Quetiapine
Sir: I would like to correct several errors in the recent ACA-DEMIC HIGHLIGHTS report on atypical antipsychotics 1 with respect to quetiapine fumarate (Seroquel):
(1) The reference cited for the "long-term study" (Cantillon and Arvanitis 2 ) is incorrect. The correct reference should be Arvanitis and Rak. 3 (2) While this was a 52-week trial on efficacy, safety, and tolerability of quetiapine in elderly subjects with psychotic disorders, the data actually presented at the American Psychiatric Association meeting were from a 12-week interim analysis of this study. No long-term data were presented. (3) The patient numbers referred to in the article, i.e., 12 patients completed 16 weeks of treatment and 6 patients completed a year of treatment, are incorrect. The correct patients numbers to cite from the 12-week interim analysis are as follows: 151 patients were enrolled and received trial medication, 36 (24%) patients withdrew from the trial: 13 (9%) had adverse events, 12 (8%) refused to continue or were lost to follow-up, 9 (6%) withdrew because of lack of effect, and 2 (1%) because of protocol noncompliance. (4) Citing the frequency of side effects from this study as being "quite high" is misleading, and the numbers presented were totally inaccurate. The correct numbers for the side effects mentioned should be: agitation 11% (not 53% as cited), somnolence 32% (not 40% as cited), and constipation 8% (not 27% as cited).
Quetiapine is an atypical antipsychotic agent that is effective against both the positive and negative symptoms of schizophrenia, with an excellent tolerability and safety profile including no treatment-emergent extrapyramidal side effects or increases in serum prolactin levels across the entire antipsychotic dose range. It is this profile that makes quetiapine an attractive alternative to standard agents, particularly in elderly patients who are especially sensitive and cannot tolerate the motor side effects often associated with antipsychotic therapy. It is for these patients I would like to set the quetiapine record straight so that it appropriately reflects the enthusiasm that has been shown in the psychiatric community for this beneficial drug.
Prakash S. Masand, M.D.
Los Angeles, California
Hyperglycemia Associated With Olanzapine
Sir: Olanzapine, a thienobenzodiazepine, is an atypical antipsychotic agent similar to clozapine, risperidone, and quetiapine in that it selectively binds to serotonin receptors. It also has an affinity for the D 2 , D 4 , D 1 , muscarinic, α 1 -adrenergic, and H 1 histaminic receptors. 1 Olanzapine is well tolerated and has a safety profile associated with a low incidence of extrapyramidal movements and agranulocytosis. infrequently (1/100 to 1/1000). 2 We describe a patient who developed hyperglycemia 6 weeks after beginning olanzapine therapy, which resolved upon discontinuation of the drug and reappeared after rechallenge.
Case report. Mr. A, a 32-year-old mentally retarded African American man, had a 4-year history of personality disorder and psychotic disorder characterized by stress-induced hallucinations. He was started on olanzapine, 10 mg q.h.s. Mr. A also had a history of polysubstance and alcohol abuse. Significant medical findings included obesity (height = 67", weight = 99.5 kg), history of borderline hypertension (medication-free), chronic active hepatitis C, chronic allergic rhinitis, and positive tuberculin skin test.
Mr. A did not have a prior personal or family history of diabetes mellitus or glucose intolerance, although hypertension, race, and obesity could predispose him to these conditions. Prior to beginning olanzapine therapy, Mr. A was taking the following medications: fluphenazine, 15 mg/day; benztropine, 4 mg/day; and beclomethasone nasal spray, 1 spray in each nostril b.i.d. (168 µg/day). After Mr. A started olanzapine therapy, fluphenazine was decreased to 10 mg q.h.s. for 7 days and then to 5 mg q.h.s. for 7 days before being discontinued. Benztropine was tapered down to 1 mg/day and subsequently discontinued because Mr. A did not have extrapyramidal symptoms during olanzapine therapy. Olanzapine was started at 10 mg q.h.s. with subsequent titration to 15 mg q.h.s. at 3 weeks and 20 mg q.h.s. at 9 weeks.
After 6 weeks of olanzapine therapy, a routine chemistry panel revealed an elevated blood glucose level of 290 mg/dL. This was to our knowledge the first incidence of hyperglycemia in this patient, as previous fasting blood glucose levels were less than 100 mg/dL. Subsequent fasting blood sugar levels over the next month ranged from 300 to 402 mg/dL, and hemoglobin A 1c was 13.8% (normal < 6.5%). Initially, Mr. A was placed on a sliding scale insulin regimen. Blood glucose levels were not controlled on this regimen; therefore, beclomethasone nasal spray was stopped, olanzapine was decreased to 15 mg q.h.s., and NPH human insulin 15 units SQ each morning was started. Daily Accucheck (fingerstick) readings continued to be elevated, which necessitated the titration of NPH human insulin to 32 units SQ each morning and 12 units SQ each day at 4 p.m. Olanzapine was discontinued after 13 weeks of therapy, and Mr. A began a trial of chlorpromazine at an initial dose of 45 mg/day. Blood glucose levels returned to normal approximately 2 weeks after olanzapine was stopped and averaged 103 mg/dL over the next several months, thus permitting discontinuation of insulin.
Mr. A was rechallenged with olanzapine, 5 mg q.h.s., 8 months after his first trial. Rechallenge resulted in hyperglycemic episodes once again. Eight days after olanzapine was restarted, Mr. A's fasting blood glucose level was 254 mg/dL. Insulin was not prescribed at that time. Olanzapine was stopped, and chlorpromazine was titrated up to 150 mg/day. Blood glucose levels returned to normal several weeks after discontinuation of olanzapine, and daily Accuchecks were discontinued.
This case is significant because the hyperglycemia required insulin therapy, resolved after olanzapine was stopped, and recurred upon rechallenge. There did not seem to be a doseeffect relationship in this patient, since fasting blood glucose levels were similar with olanzapine dosages of 15 mg q.h.s. and 20 mg q.h.s.
High-dose systemic glucocorticoids have been shown to induce hyperglycemia in some patients; however, Mr. A was using a topical glucocorticoid formulation, nasal beclomethasone. 3 Topical glucocorticoids have not been associated with significant alterations in blood glucose concentrations. 3 In this case, Mr. A stopped using beclomethasone several weeks before the first trial of olanzapine was discontinued, and his blood glucose levels remained elevated.
As noted previously, Mr. A had chronic active hepatitis C. Glucose intolerance has been noted in patients with liver disease; however, Mr. A had no prior episodes of hyperglycemia. 4 Given his medical history, it is possible that Mr. A had unrecognized type 2 diabetes.
Induction of hyperglycemia has been reported with the traditional antipsychotics chlorpromazine, loxapine, and amoxapine. 5, 6 Several authors have proposed hypotheses for antipsychotic-induced hyperglycemia; however, conclusive evidence is still lacking. [5] [6] [7] [8] It is interesting to note that clozapine has been associated with hyperglycemia in 7 separate case reports, 6 of which involved African American individuals.
9-12
Most of the affected patients developed hyperglycemia 5 to 8 weeks after starting clozapine, with normalization of blood glucose levels occurring after discontinuation of clozapine.
9,10 Two patients were rechallenged with clozapine and experienced hyperglycemic episodes after 3 to 10 days of therapy.
9,11 On the basis of these findings, this case report suggests that the induction of hyperglycemia by clozapine and olanzapine occurs in a similar temporal pattern with initial therapy as well as rechallenge therapy.
Since this letter was accepted for publication, 2 olanzapineand 4 clozapine-associated diabetes cases have been published. 13 There are several similarities between the current case and the olanzapine cases of Wirshing and associates. Although only 1 case patient had a positive family history for diabetes, to date, all of the olanzapine-induced hyperglycemia cases have occurred in obese, male patients. In addition, 2 of the 3 olanzapine patients were African Americans. This is suggestive that patients typically at risk for insulin resistance based on race or obesity may be at greater risk for olanzapine-induced hyperglycemia. The olanzapine was not discontinued in the patients of Wirshing and colleagues, but rather their hyperglycemia was controlled with medication; therefore, it is not known whether the drug-induced diabetes would have resolved upon olanzapine discontinuation as was observed in the current case. Further studies are needed to determine the effect of olanzapine and other atypical agents on glycemic control. ; however, interpretation of these findings has been limited by methodological problems in the existing research. 2 The mechanism of action of St. John's wort is unknown, although serotonin reuptake inhibition has been suggested as a basis for its moodelevating effects. 3, 4 One of the herb's attractions has been its relative safety and tolerability compared with standard antidepressant therapy.
1 I report a case of St. John's wort inducing a hypomanic mixed state in a patient who suffered from panic disorder and depression.
Case report. Ms. A, a 47-year-old woman, presented with an 8-year history of nocturnal panic attacks. She described awakening each night sweating, anxious, tachycardic, and feeling panicked. As her symptoms worsened, she noted onset of depressive symptoms, including feelings of sadness, worthlessness, decreased concentration, poor memory, and periodic suicidal thoughts. She obtained relief from her panic and depressive symptoms with alprazolam, 0.25 mg/day, and paroxetine, 20 mg/day. At the time of initial assessment, Ms. A met DSM-IV criteria for panic disorder and unipolar major depression.
Ms. A continued with complete relief of her symptoms on paroxetine treatment for several months, but complained of fatigue and anorgasmia. Her medication was switched to sertraline, which was titrated to 75 mg/day. She noted feeling "a thousand times better" on sertraline treatment, continued to have relief from her panic symptoms, and no longer felt fatigued. However, her sexual side effects persisted. After several months, Ms. A began exhibiting significant irritability and insomnia. Sertraline was decreased to 50 mg, and the new symptoms resolved.
Ultimately, Ms. A discontinued sertraline because of sexual side effects. After waiting a week, and allowing the side effects to resolve, she started taking St. John's wort, a 0.1% tincture solution that she purchased at a health food store. She followed the instructions on the label, but after 10 days noticed racing and distorted thoughts, increased irritability, hostility, aggressive behavior, and decreased need for sleep. She described "feeling speedy" and began driving aggressively; she later described her state as one of "radical agitation." Ms. A discontinued the St. John's wort and noted complete resolution of her symptoms in 2 days.
Although she lacked a prior history of mania or hypomania, Ms. A demonstrated a vulnerability to activation while taking moderate doses of sertraline. The activation resolved completely during the sertraline washout and recurred 10 days after initiation of St. John's wort. Thus, there is a clear temporal association between the onset of hypomanic symptoms and the use of St. John's wort. It is unlikely that sertraline withdrawal or a sertraline-St. John's wort interaction accounted for the second hypomanic episode, given the washout period and the resolution of Ms. A's symptoms in the interval. 5 This case suggests that St. John's wort can cause one of the complications associated with antidepressants, namely induction of hypomania and mixed states. 6 As many patients attempt to seek alternative treatments for their depression, clinicians should caution patients that herbal remedies are not without potentially serious side effects. The edema remained stable after discontinuing diuretics and lowering the risperidone dose to 6 mg/day, and resolved entirely within 1 week of reducing the dose to 2 mg/day. Ms. A's condition quickly deteriorated, though, prompting a return of the risperidone dosage to 8 mg/day. One week later, the edema had returned, accompanied by a 15-lb (6.5-kg) weight gain. Risperidone was discontinued over the following week, and the edema resolved without diuretics.
Risperidone thus appeared to cause generalized (primarily dependent) edema in a dose-related fashion. As in the previously reported case, 1 edema was noted when risperidone was added to a regimen including valproate and a benzodiazepine. We examined the other 10 inpatients at our facility taking both risperidone (2-14 mg/day) and valproate and found no peripheral edema.
We encourage others to be alert to this complication of risperidone, which perhaps only occurs when coadministered with valproate and/or benzodiazepines.
